Randomized Clinical Trial (RCT) on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial

The purpose of this study is to test the feasibility i. e. to examine all aspects necessary for the implementation of a future randomized clinical trial that aims to determine whether non-surgical periodontal treatment can be improved by concomitant intake of vitamin D.

Study Overview

• Status: Not yet recruiting
• Conditions: Inflammation; Periodontitis; Periodontal Diseases; Vitamin D; Periodontal Inflammation; Inflammation Gum
• Intervention / Treatment: Dietary supplement: Vitamin D supplementation (30 µg/d)

Detailed Description

Vitamin D is believed to have anti-inflammatory and anti-bacterial properties. This is hypnotized to play a role in periodontitis. Well-designed RCTs on this theme are lacking. We therefore aim at testing a proposed study design in a pilot study, on vitamin D supplementation and its possible adjunctive effect on non-surgical periodontitis treatment (NSPT).

Altogether 28 patients with a referral for treatment at the Public Dental Service Competence Center of Northern Norway (TkNN), diagnosed with periodontitis Stage I-IV, and within the ages of 20-60 years will be recruited. Participation is voluntary and based on written informed consent.

The participants will randomly be allocated into two groups of equal sizes. The intervention group will receive vitamin D supplementation of 30 µg/day, and the control group will receive placebo tablets. The study is double-blinded.

The participants will be instructed to take the tablets once a day for four weeks prior to the onset of the NSPT, and for two additional weeks after their first NSPT, altogether six weeks. The aim is to ensure that the vitamin D status among those who receive vitamin D supplementation is satisfactory at the start of NSPT and throughout the NSPT period.

At baseline and before the start of intervention a dentist will perform a periodontal examination, including bleeding on probing (BoP), probing pocket depth (PPD), determine lost teeth, mobility, furcation involvement and radiographic bone loss. Clinical measurements in addition to data on age and sex will be obtained from the clinics (TkNN) own medical record system. The participants will also be asked to fill out a digital questionnaire about weight and height, oral hygiene, oral health, and general health. The questions in the questionnaire will be repeated at the end of follow-up, in addition to questions on the whether or not the participants have taken the tablets as prescribed, their experienced in doing so, and finally on behaviors that affect vitamin D status (taken other supplements / use of solarium / sun holidays).

At baseline, at week five and at the end of the study period, gingival crevicular fluid (GCF) and blood samples from blood vessels in the arm will be sampled and analyzed for their content of vitamin D, inflammatory markers and enzymes. As a secondary outcome we also aim to assess the correlations between levels of inflammatory markers in blood and the GCF.

The duration of follow-up depends on how many treatments the dentist considers the patient will need. This is part of the ordinary treatment regimen offered to this patient group. The treatment will take place over a time-period of one month. The patient is then invited to return for a check-up after 6-8 weeks. The total estimated time that each individual will be involved in the study is approximately 11-13 weeks.

Once the pilot study is completed, all steps (both scientific and practical) of the trial will be evaluated in details to assess what worked / did not work / could have worked better - including recruitment, randomization, follow-up, dropout, reason for dropout, patient compliance, side effects, GCF and blood samples; including sampling storage, shipping, analysis and more.

The benefits of running a feasibility trial is that it provides valuable insight and knowledge useful for designing and conducting a future high quality clinical trial on this topic. If vitamin D is confirmed to improve the effect of NSPT in a future clinical trial, improving vitamin D status in patients would be an easy to carry out means in the fight against this disease.

• Study Type: Interventional
• Enrollment (Anticipated): 28
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Magritt Brustad, Dr. Scient; Phone Number: +47 77 64 48 43; Email: magritt.brustad@uit.no

Study Locations

• Norway
  • Postboks 2406
    • Tromsø, Postboks 2406, Norway, 9271
      • Public Dental Service Competence Centre of Northern Norway
      • Contact: Gro Eirin Holde, CandOdontPhD; Phone Number: +47 960 92 090; Email: gro.eirin.holde@tffk.no

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients diagnosed with chronic periodontitis according to the 2017 case definition
• Adults, age group 20-60 years
• Periodontitis Stage I-IV (2017 definition)

Exclusion Criteria:

• Systemic illnesses (diabetes, osteoporosis)
• Smoking
• Immuno-suppressive treatment
• Pregnancy
• Daily vit-D supplements
• Solarium
• NSPT within 6 months
• Local anti-microbial treatment
• No natural teeth/peri implantitis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Vitamin D3 (30 µg/d); Subjects will take 30 µg vitamin D3 per day	Dietary supplement: Vitamin D supplementation (30 µg/d); The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
PLACEBO_COMPARATOR: Placebo; Subjects will take placebo	Dietary supplement: Vitamin D supplementation (30 µg/d); The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in periodontitis status after treatment (2017 case definition)	Changes from baseline in bleeding on probing (BOP) at week 5
Change in periodontitis status after treatment (2017 case definition)	Changes in bleeding on probing (BOP) from week 5 to week 11-13
Change in periodontitis status after treatment (2017 case definition)	Changes from baseline in bleeding on probing (BOP) at week 11-13
Change in periodontitis status after treatment (2017 case definition)	Changes from baseline in probing pocket depths (PPD) at week 5
Change in periodontitis status after treatment (2017 case definition)	Changes in probing pocket depths (PPD) from week 5 to week 11-13
Change in periodontitis status after treatment (2017 case definition)	Changes from baseline in probing pocket depths (PPD) at week 11-13

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in 25(OH)D after intervention	Changes from baseline in plasma concentration of 25(OH)D at week 5
Change in 25(OH)D after intervention	Changes in plasma concentration of 25(OH)D from week 5 to week 11-13
Change in 25(OH)D after intervention	Changes from baseline in plasma concentration of 25(OH)D at week 11-13
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention	Changes from baseline in plasma and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) at week 5
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention	Changes in plasma- and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) from week 5 to week 11-13
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention	Changes from baseline in plasma- and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) at week 11-13
Change in anti-microbial peptides (LL-37, hBD-2) after intervention	Changes from baseline in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) at week 5
Change in anti-microbial peptides (LL-37, hBD-2) after intervention	Changes in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) from week 5 to week 11-13
Change in anti-microbial peptides (LL-37, hBD-2) after intervention	Changes from baseline in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) at week 11-13

Other Outcome Measures

Outcome Measure	Time Frame
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid	Correlation between biomarkers in blood and gingival crevicular fluid at baseline
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid	Correlation between biomarkers in blood and gingival crevicular fluid at week 5
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid	Correlation between biomarkers in blood and gingival crevicular fluid at week 11-13
Change in self-reported oral health before and after treatment	Changes from baseline in self-reported oral health at end of follow-up (week 11-13)

Collaborators and Investigators

• Sponsor: University of Tromso
• Collaborators: Public Dental Service Competence Center of Northern Norway
• Investigators: Principal Investigator: Magritt Brustad, Dr. Scient, Department of Community Medicine, University of Tromso

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): August 1, 2022
• Primary Completion (ANTICIPATED): December 1, 2022
• Study Completion (ANTICIPATED): December 1, 2024

Study Registration Dates

• First Submitted: May 25, 2022
• First Submitted That Met QC Criteria: May 25, 2022
• First Posted (ACTUAL): June 1, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 1, 2022
• Last Update Submitted That Met QC Criteria: May 25, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Vitamin D; Periodontitis; Cholecalciferol; 25(OH)D
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Stomatognathic Diseases; Mouth Diseases; Gingival Diseases; Periodontitis; Inflammation; Gingivitis; Periodontal Diseases; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Vitamin D
• Other Study ID Numbers: 2022/440018

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No